Invesco Ltd. Has $1.06 Million Stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Invesco Ltd. lifted its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 2.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 42,101 shares of the biopharmaceutical company’s stock after buying an additional 871 shares during the quarter. Invesco Ltd. owned about 0.06% of Celldex Therapeutics worth $1,064,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. Vanguard Group Inc. lifted its position in shares of Celldex Therapeutics by 0.3% during the fourth quarter. Vanguard Group Inc. now owns 3,881,995 shares of the biopharmaceutical company’s stock valued at $98,098,000 after purchasing an additional 12,213 shares in the last quarter. American Century Companies Inc. lifted its stake in Celldex Therapeutics by 46.5% in the 4th quarter. American Century Companies Inc. now owns 608,457 shares of the biopharmaceutical company’s stock worth $15,376,000 after purchasing an additional 193,093 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Celldex Therapeutics by 1.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 544,330 shares of the biopharmaceutical company’s stock worth $13,755,000 after buying an additional 5,474 shares in the last quarter. Fisher Asset Management LLC boosted its position in shares of Celldex Therapeutics by 20.9% during the 4th quarter. Fisher Asset Management LLC now owns 452,497 shares of the biopharmaceutical company’s stock valued at $11,435,000 after acquiring an additional 78,145 shares during the last quarter. Finally, Barclays PLC lifted its position in Celldex Therapeutics by 140.7% during the third quarter. Barclays PLC now owns 130,381 shares of the biopharmaceutical company’s stock valued at $4,431,000 after purchasing an additional 76,207 shares during the last quarter.

Celldex Therapeutics Stock Down 0.6 %

Shares of NASDAQ CLDX opened at $20.71 on Friday. Celldex Therapeutics, Inc. has a 52-week low of $14.40 and a 52-week high of $47.00. The stock has a market capitalization of $1.37 billion, a P/E ratio of -8.06 and a beta of 1.59. The firm’s 50-day moving average price is $19.10 and its two-hundred day moving average price is $23.27.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.02. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. The business had revenue of $1.18 million during the quarter, compared to analyst estimates of $1.25 million. As a group, equities research analysts expect that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on CLDX. UBS Group started coverage on Celldex Therapeutics in a research note on Thursday, February 13th. They set a “buy” rating and a $44.00 price objective for the company. Canaccord Genuity Group initiated coverage on Celldex Therapeutics in a research note on Monday. They issued a “buy” rating and a $64.00 price target on the stock. The Goldman Sachs Group lowered their target price on shares of Celldex Therapeutics from $42.00 to $36.00 and set a “neutral” rating for the company in a report on Monday, March 3rd. Cantor Fitzgerald reissued an “overweight” rating and set a $67.00 price objective on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. Finally, HC Wainwright reissued a “buy” rating and issued a $80.00 target price on shares of Celldex Therapeutics in a report on Friday, February 28th. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Celldex Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $55.30.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.